The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...
Highlights from the Systemic Lupus International Collaborating Clinics World Lupus Seminar on Africa
Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...
21hon MSN
Anxiety is a common issue affecting youth. With more than 40% of children affected by chronic medical conditions and the ...
Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...
EAST HANOVER, NJ, USA I March 20, 2025 I Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) ...
Zacks.com on MSN16h
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease DrugThrough the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...
In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...
In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...
Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the ...
TipRanks on MSN19h
Syncona’s Autolus Reports Strong 2024 Results and Strategic AdvancesSyncona Shs GBP ( ($GB:SYNC) ) has provided an announcement. Autolus Therapeutics, a portfolio company of Syncona Ltd, has announced its 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback